- Home
- MNDO vs RLYB Comparison
MNDO vs RLYB Comparison
Compare MNDO & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNDO
- RLYB
- Stock Information
- Founded
- MNDO 1995
- RLYB 2018
- Country
- MNDO Israel
- RLYB United States
- Employees
- MNDO N/A
- RLYB N/A
- Industry
- MNDO EDP Services
- RLYB Biotechnology: Pharmaceutical Preparations
- Sector
- MNDO Technology
- RLYB Health Care
- Exchange
- MNDO Nasdaq
- RLYB Nasdaq
- Market Cap
- MNDO 24.2M
- RLYB 24.1M
- IPO Year
- MNDO 2000
- RLYB 2021
- Fundamental
- Price
- MNDO $1.17
- RLYB $0.59
- Analyst Decision
- MNDO
- RLYB Hold
- Analyst Count
- MNDO 0
- RLYB 2
- Target Price
- MNDO N/A
- RLYB N/A
- AVG Volume (30 Days)
- MNDO 31.3K
- RLYB 385.4K
- Earning Date
- MNDO 11-04-2025
- RLYB 11-06-2025
- Dividend Yield
- MNDO 18.49%
- RLYB N/A
- EPS Growth
- MNDO N/A
- RLYB N/A
- EPS
- MNDO 0.15
- RLYB N/A
- Revenue
- MNDO $20,155,000.00
- RLYB $761,000.00
- Revenue This Year
- MNDO N/A
- RLYB N/A
- Revenue Next Year
- MNDO N/A
- RLYB N/A
- P/E Ratio
- MNDO $7.93
- RLYB N/A
- Revenue Growth
- MNDO N/A
- RLYB 154.51
- 52 Week Low
- MNDO $1.02
- RLYB $0.22
- 52 Week High
- MNDO $2.13
- RLYB $1.24
- Technical
- Relative Strength Index (RSI)
- MNDO 40.43
- RLYB 54.33
- Support Level
- MNDO $1.16
- RLYB $0.58
- Resistance Level
- MNDO $1.22
- RLYB $0.62
- Average True Range (ATR)
- MNDO 0.03
- RLYB 0.04
- MACD
- MNDO 0.01
- RLYB -0.00
- Stochastic Oscillator
- MNDO 16.67
- RLYB 70.71
About MNDO MIND C.T.I. Ltd.
MIND C.T.I. Ltd develops, manufactures, markets, and implements real-time and off-line convergent billing and customer care software solutions. It derives revenue from the sale of software products and services in two reportable segments, namely Billing and Related Services, which derives key revenue, and Messaging. The company has three product lines: Product Line A- billing and customer care solutions for service providers; Product Line B - call accounting and call management solutions for enterprises; and Product Line C - mobile messaging, communication, and payment solutions. Geographically, the company operates in the Americas, Europe, Asia Pacific and Africa, and Israel. It earns maximum revenue from Europe.
About RLYB Rallybio Corporation
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The programs of the company are for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.